Publications by authors named "N Chaar"
Background: Patients with advanced prostate cancer (PC) commonly experience fatigue related to the disease itself and its treatment, which affects their quality of life. There are limited real-world data available on patients' experiences of fatigue while receiving PC treatment and its management.
Patients And Methods: This was a cross-sectional, noninterventional qualitative study involving individual concept-elicitation interviews with patients in the United States.
Article Synopsis
- The study investigates the real-world occurrence of adverse events (AEs) in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving various treatments, reflecting a gap between current recommendations and actual practice.
- Data was collected from a large claims review in the U.S. between January 2014 and June 2021, focusing on 10 common AEs that significantly affect patient outcomes.
- A total of 4,145 patients were analyzed, with different treatment groups including ADT alone, ADT with nonsteroidal anti-androgens, docetaxel, and androgen receptor pathway inhibitors, enabling a comparison of AEs across these groups.
Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC. This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.
View Article and Find Full Text PDFBackground: Few phase 3 studies have evaluated optimal systemic treatment strategies for patients with oligometastatic hormone-sensitive prostate cancer (HSPC), who may be at risk of undertreatment.
Objective: To evaluate outcomes for patients with oligometastatic and polymetastatic HSPC treated with enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT.
Design, Setting, And Participants: This was a post hoc analysis of data for 927 patients with nonvisceral metastatic HSPC in the ARCHES trial (NCT02677896).
Purpose: We evaluate utilization of treatment intensification of androgen deprivation therapy with androgen receptor pathway inhibitor/docetaxel for metastatic castration-sensitive prostate cancer patients across physician specialties.
Materials And Methods: This retrospective study identified patients with metastatic castration-sensitive prostate cancer in the Optum Research Database between 2014 and 2019. Adult men with ≥1 claim for metastatic disease within 90 days before or any time after the first prostate cancer claim who received androgen deprivation therapy were included.